Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4620 - Relationship between pretreatment levels of circulating DNA, circulating tumor cells, CEA, CA19.9 and tumor burden on CT scan in patients treated for a metastatic colorectal cancer


09 Sep 2017


Poster display session


Staging Procedures (not Imaging);  Translational Research;  Colon and Rectal Cancer


Melanie Hassine


Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393


M. Hassine1, C. Savoye-Collet2, D. Sefrioui1, L. Beaussire3, A. Gillibert4, A. Gangloff1, N. Sarafan-Vasseur3, P. Michel1, F. Di Fiore1

Author affiliations

  • 1 Gastroenterology, CHU Hôpitaux de Rouen-Charles Nicolle, 76031 - Rouen/FR
  • 2 Radiology, Rouen University Hospital, 76000 - rouen/FR
  • 3 Institute For Biomedical Research And Innovation, Inserm U1245, University of Rouen, 76000 - rouen/FR
  • 4 Biostatistics, Rouen university hospital, 76000 - rouen/FR


Abstract 4620


Circulating DNA has been reported as prognostic in metastatic colorectal cancer (mCRC) but its correlation with tumor burden has never been clearly established. The aim was to evaluate the correlation between pretreatment levels of circulating tumor DNA (ctDNA), cell-free-DNA (cfDNA), circulating tumor cells (CTC), CEA, CA19.9 with tumor characteristics on CT scan.


It was a retrospective analysis from a prospective trial on circulating markers (ctDNA, cfDNA, CTC, CEA, CA19.9) at baseline in mCRC patients (NCT01212510). CT scans were centrally reviewed to assess 3 tumor parameters: the diameter using RECIST version 1.1, the total tumor length (TTL) defined as the sum of diameter of all visible lesions, and the volume (Vol) of the main lesion. Relationship between circulating markers and CT scan were analysed as well as progression-free survival (PFS) and overall survival (OS) and prognostic factors using Cox models.


A total of 83 mCRC patients were included. Median baseline ctDNA, cfDNA, CEA, CA19.9 and CTC were 21 (0.12-74) %, 36 (6-2275) ng/mL, 75 (2-64051) ng/ml, 90 (4-70900) UI/mL, and 7 (1-194)/mL, respectively. For CT scan, median value was 81 (11-310) mm for RECIST, 196 (14-1906) mm for TTL and 65 (2-783) mm3for Vol. There was a significant correlation between RECIST and CEA (p = 0.0005), CA19.9 (p = 0.007), cfDNA (p 


Circulating makers and tumor burden on CT scan were correlated and prognostic. Interventional studies are needed to evaluate the usefulness of circulating makers in decision making.

Clinical trial identification


Legal entity responsible for the study

Rouen University Hospital


Merck, Roche and Amgen


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.